6 March 2018 - - Cambridge, Massachusetts-based cellular immunotherapy developer Unum Therapeutics Inc. has appointed Christiana Stamoulis to the additional role of president, the company said.
Stamoulis has been Unum's chief financial officer (CFO) and head of corporate development since joining the company in January 2015.
In her role as president and CFO, she is responsible for Unum's business functions including finance, corporate and business development, corporate strategy, legal, investor relations and corporate communications.
Prior to joining Unum, Stamoulis was the senior vice president of corporate strategy and business development and a member of the executive team at Vertex Pharmaceuticals, Inc.
Prior to Vertex, she served as a managing director in the investment banking division of Citigroup. Before that, she was a senior investment banker in the healthcare group of the investment banking division of Goldman, Sachs and Co.
Stamoulis received two bachelor degrees from the Massachusetts Institute of Technology and her MBA from MIT's Sloan School of Management.
Unum Therapeutics uses its proprietary antibody-coupled T cell receptor (ACTR) technology in combination with tumor-targeting antibodies to activate the body's immune system to fight cancer.
The company is actively building a pipeline of ACTR programs in combination with a wide range of proprietary, tumor-targeting antibodies for use in both hematologic and solid tumor indications.